Announcements 06

CLINICAL LABORATORY NEWS SPECIAL EDITION 9

The American Association for Clinical Chemistry extends its sincere thanks to the following companies for their

generous support through their contributions.

Abbott Diagnostics■ Registration Portfolios■ Hotel Keycards (selected hotels)■ Educational Sessions

ACON Laboratories, Inc.■ Exhibitor Lanyards

Bayer HealthCare, Diagnostics Division■ AACC Lectureship Award■ Award for Outstanding Contributions to Clinical Chemistry■ The Morton K. Schwartz Award for Significant Contributions in Cancer Research Diagnostics

BD Diagnostics, Preanalytical Systems■ International Travel Fellowship

Beckman Coulter, Inc.■ Award for Outstanding Contributions through Service to the Profession of Clinical Chemistry

Bio-Rad Laboratories■ Workshop Refreshments

Cardinal Health, Scientific Products Distribution■ Past President’s Award

Dade Behring, Inc.■ Edwin F. Ullman Award for Technological Innovation■ Notepads and Pens

Diagnostic Products Corporation■ Sigi Ziering Award for Outstanding Contribution for a Publication in the Journal Clinical Chemistry

Diagnostica Stago, Inc.■ ClinPack Door Drop Bags (selected hotels)

DiaSorin■ Educational Session

Fujirebio Diagnostics, Inc.■ Attendee Lanyards

IVD Technology Magazine/Canon Communications■ International Marketing Seminar

Olympus America, Inc., Diagnostic Systems Group■ Exhibit Hall Refreshment Breaks■ Lead Retrieval Cards■ Award for Outstanding Contributions in Selected Area of Research

Ortho-Clinical Diagnostics■ Program and Exhibit Guides■ Award for Outstanding Clinical Laboratory Contributions to Patient Safety

Quest Diagnostics Hospital Services■ Award for Outstanding Contributions in Education

Roche Diagnostics■ Award for Outstanding Scientific Achievements by a Young Investigator

As of June 2006

10 CLINICAL LABORATORY NEWS SPECIAL EDITION

The AACC Lectureship Award

Sponsored by an educational grant from Bayer HealthCare Diagnostics Division

Harvey V. Fineberg, MD, PhD

Dr. Fineberg is president of the Institute of Medicine of the National Academy of Sciences in Washington, D.C. He served as provost of Harvard University from 1997 to 2001, follow-

ing 13 years as dean of the Harvard School of Public Health. He has devoted most of his academic career to the fields of health policy and medical decision making. Dr. Fineberg helped found and served as president of the Society for Medical Decision Making and also served as adviser and consultant to the U.S. Centers for Disease Control and Preven-tion and the World Health Organization. At the Institute of Medicine, he has chaired and served on a number of panels dealing with health policy issues, ranging from AIDS to vaccine safety. He is the author, co-author, and co-editor of numerous books and ar-ticles on such diverse topics as AIDS pre-vention, tuberculosis control, assessment of new medical technology, clinical and public health decision making, and understanding risk in society.

Award for Outstanding Contributions To Clinical Chemistry

Sponsored by Bayer HealthCare Diagnostics Division

Helen M. Free, DSc

Dr. Free has spent her entire scientific career of more than 60 years at Bay-er Healthcare Diagnostics Division (formerly Miles Laboratories) in Elkhart, Ind., where she continues

as a professional relations consultant in the diabetes care division. Her work has ranged from her start as a control chemist to senior new products manager of microbiologi-cal test systems to director of specialty test systems to director of marketing services. She has taught management at Indiana Uni-versity at South Bend for 20 years. She has served AACC in many capacities, includ-ing two terms on the board of directors; as a member of the Professional Relations Commission, Nominating Committee, and Public Relations Committee; as chair of the Committee on Divisional Affairs and Chi-cago Section; and as president in 1990. She is a past president of the National Registry of Certified Chemists. Dr. Free is a 50-year member of the American Chemical Soci-ety (ACS), which she served as president in 1993. The ACS presented her its Garvan Medal for distinguished service to chemistry by a woman, and in her honor, instituted the Helen M. Free Award in Public Outreach in

1995 (she was the first recipient). She is a fellow of the American Association for the Advancement of Science, the American In-stitute of Chemists, and the Royal Society of Chemistry. Dr. Al Free, her late husband of nearly 53 years, was also a Bayer chemist. To-gether, they are enshrined in the Science and Engineering Hall of Fame and the National Inventors Hall of Fame.

Award for Outstanding Clinical Laboratory Contributions to Patient Safety

Sponsored by Ortho-Clinical Diagnostics

Michael L. Astion, MD, PhD

Dr. Astion is a clinical pa-thologist who is an associ-ate professor and director of reference laboratory services at the University of Washington Department of Laboratory Medicine in

Seattle. His career is equally divided between teaching, clinical service, and research and development. He has authored more than 20 software titles and more than 30 papers. His software includes both laboratory tu-torials and competency assessment exams, and these materials are now used by more than 15,000 clinical laboratory workers each year. He is the editor-in-chief of Laboratory Errors and Patient Safety, a newsletter dedi-cated to improving laboratory quality. Dr. Astion is a frequent speaker at professional meetings, where he lectures on issues related to laboratory test interpretation, autoan-tibody testing, medical errors, medical in-formatics, and competency assessment. His previous awards include the American Soci-ety for Clinical Laboratory Science’s Theriot Award for Excellence in Media, which he re-ceived twice for his educational software. A frequent winner of the AACC outstanding speaker award, Dr. Astion has been active in AACC, including as a symposium organizer on the 2005 Annual Meeting Organizing Committee. He currently heads the AACC patient safety task force.

Award for Outstanding Contributions in Education

Sponsored by Quest Diagnostics Nichols Institute

Catherine A. Hammett-Stabler, PhD, DABCC, FACB

Dr. Hammett-Stabler is director of the clinical toxicology, clinical phar-macology, and pediatric metabolism laboratories and associate director of the core laboratory of

the McLendon Clinical Laboratories at the University of North Carolina Hospital in Chapel Hill. As an associate professor in the department of pathology and laboratory medicine at the University of North Caro-

lina, her responsibilities focus on service and education. She teaches a variety of UNC students, including undergraduates in the clinical laboratory science program, second-year medical and dental students, graduate students, residents, and fellows. She often presents programs and lectures covering a range of laboratory topics to other health-care providers, including clinicians, nurses, and clinical laboratory scientists. She is co-director of the University of North Carolina Hospital’s postdoctoral training program in clinical chemistry. An AACC member since 1982, Dr. Hammett-Stabler has served on a number of committees, including the 2000 and 2003 Annual Meeting Organizing Committees. She chaired the editorial board of Clinical Chemistry News. She is past-chair of the TDM and Toxicology Division, where she has held many other positions as well. Dr. Hammett-Stabler serves on the board of directors of the American Board of Clinical Chemistry and the National Registry of Cer-tified Chemists. She is a member of several editorial boards, including Clinica Chimica Acta and Therapeutics and Toxins, and is an associate editor of Clinical Biochemistry.

The Morton K. Schwartz Award for Significant Contributions in Cancer Research Diagnostics

Sponsored by Bayer Healthcare Diagnostics Division

Herbert A. Fritsche, PhD, FACB

Dr. Fritsche has served as chief of clinical chemistry at M.D. Anderson Cancer Center in Houston for the past 37 years. He has served in all elected po-sitions in AACC’s Texas

Section and chaired the national Education Committee and the Education Committee of the Immunology Division. He has served as president of the Clinical Ligand Assay So-ciety and is a member of the editorial board of six journals. He has lectured at many international meetings and has published more than 150 papers and 30 book chap-ters in the field of cancer diagnostics. He is a member of the scientific advisory boards of six companies; holds four patents and two patent applications; is co-author of a recent textbook, Tumor Markers; and is the meeting director of a biennial conference on cancer diagnostics sponsored by M.D. Anderson. He has been active in the field of cancer di-agnostics since 1969. He was one of the early proponents of the direct serum assay for carcinoembryonic antigen (CEA) for breast cancer monitoring. He was one of the first to develop immunonephelometric assays for serum immunoglobulins and to apply the beta-2 microglobulin assay for multiple myeloma, to implement the serum lactate dehydrogenase-1 assay as a complement to alpha-fetoprotein and human chorionic gonadotropin for monitoring patients with germ cell tumors, and to use serum pros-

tate specific antigen for the early detection and clinical management of prostate cancer. Recently, he helped to develop the assay for the circulating tumor cell and established its utility as a prognostic marker for patients with metastatic breast cancer. Dr. Fritsche participated in the clinical trials leading to Food and Drug Administration clearance of all of the serum tumor marker tests currently in use. His current work focuses on the role of circulating DNA as a tumor marker.

Award for Outstanding Contributions Through Service to the Profession of Clinical Chemistry

Sponsored by Beckman Coulter, Inc.

Gary L. Myers, PhD, FACB

Dr. Myers is chief of the clinical chemistry branch at the Centers for Disease Control and Prevention in Atlanta. He also serves as the scientific director of the World Health Or-

ganization Collaborating Center for Refer-ence and Research in Blood Lipids at the CDC. His 30-year career at the CDC has focused on improving the laboratory mea-surement of biochemical markers used to assess chronic disease risk, particularly car-diovascular disease. As the CDC’s represen-tative on the National Cholesterol Educa-tion Program’s Laboratory Standardization Panel, he played a pivotal role in developing national guidelines to improve the reliabil-ity of cholesterol testing. He organized the Cholesterol Reference Method Laboratory Network, which has been a model for other such efforts. Dr. Myers has served AACC at all levels. He is currently president-elect and recently completed a three-year term on the board of directors. He chaired the Lipids and Lipoproteins Division, which presented him the Gerald R. Cooper Award for Out-standing Service. He chaired the 2002 An-nual Meeting Organizing Committee and the 2006 Beckman Conference. Dr. Myers has served on many AACC committees. He chairs the National Academy of Clinical Biochemistry’s Committee for a Laboratory Medicine Practice Guideline for Emerging Cardiac Markers and is involved with vari-ous other national and international orga-nizations dealing with laboratory measure-ment and standardization issues. He serves on the National Kidney Disease Education Program’s Laboratory Working Group, the American Diabetes Association’s Insulin Standardization Working Group, the Inter-national Federation of Clinical Chemistry’s Working Group on Hemoglobin A1c Stan-dardization, and the National Institutes of Health’s C-peptide Standardization Com-mittee. Dr. Myers also serves on the board of the Clinical and Laboratory Standards Insti-tute and chairs its Global Advisory Commit-tee. He has published more than 80 articles, book chapters, and editorials.

2 0 0 6 A A C C A W A R D W I N N E R S

Clinical Laboratory Science Leaders Receive AwardsAt the opening plenary sessions of the 2006 AACC Annual Meeting, several eminent scientists were recognized for their outstanding achievements in the field of clinical laboratory science and their excellent contributions to the profession. AACC president John E. Sherwin, PhD, FACB, and representatives of the sponsoring companies presented the awards. AACC and CLN salute these leaders.

See AACC Awards, continued on page 12


Award for Outstanding Contributions In a Selected Area of Research

Sponsored by Olympus America Inc., Diagnostic Systems Group

Hugo Katus, MD

Dr. Katus is chief of inter-nal medicine and direc-tor of the cardiovascular medicine department of the University of Heidelberg in Germany. He is presi-dent-elect of the Academy

of Cardiology of the German Society of Cardiology and editor of Clinical Research in Cardiology (formerly Zeitschrift für Kar-diologie), the official journal of the German Cardiac Society. After years of work in the field, in 1984 he was the first to develop a cardiac-specific troponin assay that dem-onstrated in initial clinical trials the supe-rior performance of this marker in patients with suspected myocardial infarction. In cooperation with Boehringer Mannheim (now Roche Diagnostics), he improved the analytical performance of the troponin T assay to make it useful for large-scale clini-cal chemistry testing. He holds with Roche Diagnostics an international patent on the troponin T assay. In cooperation with clinical partners, he then showed the supe-rior performance of the troponin T assay in large randomized multi-center trials. These results documented for the first time the clinical significance of minor myocardial injury, which had remained undetected by CK-MB isoenzyme analyses. This work has markedly affected the diagnostic approaches in suspected myocardial injury and led to a new definition of myocardial infarction, which is now based on a troponin standard. Troponin measurements have also proven useful for diagnosis and risk stratification in various other disorders, such as myocarditis, heart failure, end-stage renal disease, and pulmonary embolism. In recent years, Dr. Katus’s scientific interests have shifted to the genetic basis of cardiomyopathies and heart failure. He now serves as coordina-tor of the cardiovascular genomic research initiative of the German Ministry of Science.

The Edwin F. Ullman Award

Sponsored by Dade Behring, Inc.

Larry J. Kricka, PhD

Dr. Kricka is professor of pathology and laboratory medicine at the University of Pennsylvania and direc-tor of the general chemis-try laboratory at the Hos-pital of the University of

Pennsylvania in Philadelphia. He has served AACC in countless capacities, the foremost as president in 2001. This award recognizes an individual for contributions that advance the technology of clinical laboratory sciences, and two of Dr. Kricka’s efforts, in particular, have had a profound effect on the field. The first involves chemiluminescence and bio-luminescence: He was instrumental in the development of two of the three major che-miluminescent technologies currently used in routine testing, including an enhanced luminescence system for peroxidase labels and the 1,2-dioxetane substrate, now widely

used to detect alkaline phosphatase labels and other hydrolytic enzymes. He has also played an important role in adapting che-miluminescent and bioluminescent assays to point-of-care testing. His second defining work, in collaboration with Dr. Peter Wild-ing, is with analytical microchips. Dr. Kricka played a critical role in the development of micro-fabricated clinical analysis devices and devices that isolate cells, analyze DNA, test for fertility, assist in vitro fertilization, test for drugs and hormones, and integrate tests for malignancy. These miniaturization techniques resulted in the first demonstra-tion of numerous analytically useful pro-cesses in microchips, including immunoas-say, assessment of sperm motility, and DNA amplification. Today many laboratories and companies have research and development programs based on Dr. Kricka’s discoveries. Dr. Kricka holds 30 U.S. patents and is the author or co-author of over 350 articles, ab-stracts, book chapters, and papers, and of 20 books. He is editor-in-chief of Luminescence; a member of the editorial boards of Clini-cal Chemistry, Lab-on-a-chip, and Analytical Biochemistry; and past editor of the Journal of Immunoassay.

International Travel Fellowship

Sponsored by BD Diagnostics— Preanalytical Systems

Sarfraz Ahmad, PhD

Dr. Ahmad is chief re-search scientist and re-search manager at the Florida Hospital Cancer Institute in Orlando. Be-fore joining that institu-tion in 2002, he spent ten

years in research and teaching at Loyola Uni-versity of Chicago and the University of Il-linois at Chicago’s department of medicine. Dr. Ahmad’s research and teaching interests include cellular and molecular hemostasis, thrombosis, and cancer biology, particularly related to the pathogenic mechanisms in immune disorders such as heparin-induced thrombocytopenia. His investigations are also aimed toward the development of novel anticoagulant, antithrombin, antiplatelet, and thrombolytic drugs for the manage-ment of cardiovascular/hematological pa-tients. His past research interests focused on protein/enzyme purification and charac-terization, lectin–glycoprotein interactions, pathophysiology and signaling mechanisms in sepsis/shock syndrome, interferon/cyto-kine-mediated tyrosine phosphorylation in hematopoietic cells, immune response in T-cell signaling, and skeletal muscle me-tabolism research. In these various areas of research, Dr. Ahmad has published 80 ar-ticles and book chapters and more than 200 abstracts. He is a reviewer for several bio-medical journals and has received numer-ous awards for his research contributions. Dr. Ahmad is an active member of several national and international scientific societ-ies, and has been an executive committee member of the Association of Scientists of Indian Origin in America (ASIOA) for more than a decade. He has traveled worldwide as a speaker at various national and interna-tional platforms. In addition to his ties to U.S. institutions, he has maintained inter-national research collaborations with Dan-ish, German, Indian, Italian, and Turkish biomedical institutions. He plans to use this International Travel Fellowship Award dur-

ing his educational and research activities to promote clinical chemistry in Istanbul, Tur-key, and Oslo, Norway.

The Sigi Ziering Award for Outstanding Contribution for a Publication in the Journal Clinical Chemistry

Sponsored by Diagnostic Products Corporation (DPC)

David J. Warren, PhD

Dr. Warren is a senior sci-entist in the central labo-ratory at the Norwegian Radium Hospital in Oslo. During his postdoctoral re-search at Memorial Sloan-Kettering Cancer Center,

he worked with a group that demonstrated that a neutrophil differentiation factor (G-CSF) therapy ameliorated the neutropenia associated with cytotoxic chemotherapy and accelerated neutrophil recovery following bone marrow transplantation. This growth factor is now in extensive clinical use. Dr. Warren’s research also helped to elucidate the role played by G-CSF in the pathology and therapy of a variety of inherited neutro-penic states including cyclic hematopoiesis and congenital agranulocytopenias. As a vis-iting scientist at the University of Bergen in Norway, Dr. Warren developed a number of new assays, including a unique method for the determination of the levels of cytotoxic nucleotide accumulation into the leukocyte DNA of acute lymphocytic leukemia pa-tients receiving 6-mercaptopurine mainte-nance therapy. Subsequent projects on drug metabolism led him to establish methodolo-gies for the efficient expression of recombi-nant proteins. His current research interests include the development of single-chain an-tibodies as reagents in immunometric assays for tumor marker antigens and the charac-terization of the extracellular domain of the ovarian marker CA125. His winning article, “Use of an In Vivo Biotinylated Single-Chain Antibody as Capture Reagent in an Immu-nometric Assay to Decrease the Incidence of Interference from Heterophilic Antibodies,” describes an elegant new approach to elimi-nate common inferences in immunometric methods, which if successfully implemented could produce more accurate results in these widely used tests. The paper’s co-authors were Johan Bjerner, Elisabeth Paus, Ole P. Børmer, and Kjell Nusad.

The AACC Past President’s Award

Sponsored by Cardinal Health, Scientific Products Distribution

Mitchell G. Scott, PhD, DABCC, FACB

Dr. Scott is co-medical di-rector of clinical chemistry and decentralized testing at Barnes-Jewish Hospital and professor in the divi-sion of laboratory medi-cine, in the department of

pathology and immunology at Washington University in St. Louis. He is co-director of the clinical chemistry postdoctoral training program at Washington University, where he has helped train more than 50 fellows and 100 residents. He has served AACC in many capacities, including on the Program Coordinating Commission, Meetings Man-agement Group, and executive committee of

the Clinical Chemistry Board of Editors, as well as chair of the Membership Committee and the Division Management Group. Un-der his leadership, 2005 was an exciting and busy year for AACC, as he pursued twin ma-jor goals of increasing the number of young scientists entering the field and increasing clinician awareness of AACC and laboratory medicine. The Society for Young Clinical Laboratorians speaker series began recruit-ing graduate students into the field of labo-ratory medicine, and this effort is paying off with new trainees and an increased number of postdoctoral training programs. An ini-tiative to increase interactions with clinical societies led to AACC members presenting at meetings of societies such as the Ameri-can Diabetes Association and the American Association of Clinical Endocrinologists. The National Academy of Clinical Biochem-istry and AACC completed negotiations that led to the successful merger of NACB into AACC, which will truly make the NACB the “Academy of AACC” and a place to honor members with distinguished academic ca-reers. Progress on numerous other asso-ciation efforts continued as well, including publication of all of the back issues of Clini-cal Chemistry from 1954 through 1996 on the Web site and initiation of a proteomics conference by the new Proteomics Division.

Award for Outstanding Scientific Achievements by a Young Investigator

Sponsored by Roche Diagnostics

Roshini S. Abraham, PhD

Dr. Abraham is an assis-tant professor of medicine and laboratory medi-cine and pathology at the Mayo College of Medi-cine and co-director of the clinical immunology

laboratory (where she is director of the cel-lular and molecular immunology section) at the Mayo Clinic in Rochester, Minn. Dur-ing her postdoctoral fellowship at the Mayo Clinic, she investigated the immunogenetic mechanisms that contribute to the patho-physiology of systemic lupus erythematosus and Type 1 diabetes in human leukocyte antigen (HLA) transgenic animal models as the principal investigator on two grants. She then joined the faculty, with a research focus on B cell clonal evolution and dif-ferentiation in the pathogenesis of immu-noglobulin light chain amyloidosis, a bone marrow plasma cell dyscrasia. She was also actively involved in the clinical immunology laboratory in the dysproteinemia area. Her current clinical laboratory and research in-terests are in the area of laboratory diagnosis of primary immunodeficiencies and the as-sessment of immune competence, function, and reconstitution in a variety of clinical set-tings, including solid organ transplantation, hematopoietic stem cell transplantation, immunotherapy, and cancer vaccines. She is also involved in teaching clinical immunolo-gy to graduate students, pathology residents, clinical chemistry fellows, and allied labora-tory health staff. Together with many col-laborators and trainees, she has authored 25 peer-reviewed papers and 21 abstracts. She is a manuscript reviewer for Clinical Immu-nology and the Journal of Allergy and Clinical Immunology. She received the 2003 George Grannis Young Investigator Award from the National Academy of Clinical Biochemistry (NACB). CLN

AACC Awards, continued from page 10


NACB DISTINGUISHED SCIENTIST AWARDFor Outstanding Research Advances In the Field of Clinical Biochemistry

Sponsored by Dade Behring, Inc.

Y. M. Dennis Lo, MD

Professor Dennis Lo re-ceived his preclinical medical training from the University of Cambridge. He then moved to Oxford University where he pur-sued his clinical medical

training. Following qualification, he further obtained his Doctor of Philosophy and Doc-tor of Medicine degrees from Oxford. Den-nis Lo began his academic career in Oxford as a Junior Research Fellow in Natural Sci-ences at Herford College, following by ap-pointments to the University Lectureship in Clinical Biochemistry and a Fellowship at Green College. Dr. Lo was an Honorary Consultant Chemical Pathologist at the John Radcliffe Hospital, the main teaching hospi-tal of Oxford Medical School. He returned to Hong Kong in 1997 and joined The Chi-nese University of Hong Kong (CUHK). Dr. Lo is the Associate Dean (Research) and the Dr. Li Ka Shing Professor of Medicine and Professor of Chemical Pathology of the Fac-ulty of Medicine of CUHK. He has also been recently appointed as the Director of the new Li Ka Shing Institute of Health Sciences.

Dr. Lo’s main research interest is the study of cell-free DNA and RNA molecules which exist in the plasma of human subjects. He discovered in 1997 that an unborn fetus will release its DNA into the plasma of a pregnant woman. This finding has opened up a new

approach of non-invasive prenatal diagnosis. He has also applied this strategy to the detec-tion of cancers which are common in Hong Kong, including nasopharyngeal cancer and liver cancer.

N A C B A L V I N D U B I N A W A R DFor Outstanding Contributions To the Profession and the AcademySponsored by Abbott Diagnostics

John E. Sherwin, PhD, DABCC, FACB

John Sherwin, PhD, DABCC, FACB is Chief, Genetic Disease Laboratory of the California Department of Health Services. He earned degrees at the University of Arizona, Tucson, and the

University of California, Santa Barbara, and did postdoctoral training with Dr. Masaki Furuya at the University of Tokyo and Dr. Samuel Natelson at Michael Reese Hospital in Chicago. He has held positions as hospital laboratory director, senior technical director, general manager, and chief operating officer of multimillion-dollar reference laborato-ries, and a consultant to physicians and the diagnostics industry.

Dr. Sherwin is President of AACC and has served the Association in a variety of ca-pacities including local section offices, Edu-cational Resources Committee, Committee on Pediatric Clinical Chemistry, Committee on Education, Annual Meeting Organizing Committee Co-Chair Selected Topics, Sym-posium Committee, House of Representa-tives, Council Steering Committee, Board of

Directors, Commission for Educational and Scientific Affairs (Chair), AACC Press Board of Editors, Commission on Publications (Chair), Delta Project, Governance Imple-mentation Task Force, Program Coordinat-ing Commission, and the Public Relations Program (Chair, HI5). He is a member and past newsletter editor of the Pediatric and Maternal-Fetal Division. Dr. Sherwin is also a Past-President of the National Academy of Clinical Biochemistry, a member of the NACB Finance Committee, and has served on the Publications and Nominating Com-mittee. He has served twice on the NACB Board of Directors.

N A C B G E O R G E G R A N N I S A W A R DFor Outstanding Scientific or Clinical ReportSponsored by NACB with support from the AACC Ohio Valley Section

Linnea M. Baudhuin, PhD

Linnea M. Baudhuin re-ceived her PhD in Clinical Chemistry from Cleveland State University, in con-junction with the Cleve-land Clinic Foundation, in Cleveland, Ohio in 2002.

Her graduate research projects were focused on the characterization and identification of molecular markers and signaling path-ways of lysolipids in ovarian cancer. After completing her graduate studies, Dr. Baud-huin joined the Mayo Clinic in Rochester, Minn. as a post-doctoral fellow in Clinical Chemistry and Clinical Molecular Genetics. Here, Dr. Baudhuin expanded her research interests to include novel risk markers for cardiovascular disease, molecular character-

ization of gene dosage mutations in genetic disease, and development of clinical molecu-lar genetic testing algorithms for hereditary colorectal cancer. Dr. Baudhuin joined the staff of the Mayo Clinic in 2005 as Assistant Professor of Laboratory Medicine within the Mayo Clinic College of Medicine and co-director of both Cardiovascular Laboratory Medicine and the Nucleotide Polymorphism Laboratory in the Department of Labora-tory Medicine and Pathology. Her current research interests include pharmacogenetics, molecular markers for cardiovascular and endocrine disease, and clinical cardiovascu-lar molecular genetics.

Dr. Baudhuin has published 16 peer- reviewed articles in journals such as the Jour-nal of Molecular Diagnostics, Gastroenterolo-gy, FASEB Journal, and Clinical Biochemistry as well as a book chapter in the Handbook of Cell Signaling. Dr. Baudhuin has been the recipient of several awards, including the 2004 Richard Marshall Education Award given by the Midwest Section of the AACC, the 2001 Young Investigator in Breast Can-cer Research Award and the 2001 Graduate Student Award in Research both from the Cleveland Clinic Foundation, and honorable mention at the 2001 AACC Student Poster Contest. She is currently Chair of AACC’s Society for Young Clinical Laboratorians and a diplomate of the American Board of Medical Genetics, Clinical Molecular Genetics. CLN

The NACB 2006 Award WinnersPraising the Achievements of Laboratory Leaders

Through its annual awards program, NACB, the Academy of AACC, celebrates the achievements of colleagues who have made signifi-cant contributions through scholarship and service to the profession. Chaired by Dr. Elizabeth Frank, the NACB Awards Committee wishes to thank the sponsors of these awards and to congratulate the 2006 Academy award winners.

NACB Honors New Academy FellowsThe National Academy of Clinical Biochemistry (NACB) is proud to announce the following new Academy Fellows. As NACB members these distinguished scientists are all doctorate-level professionals dedicated to enhancing the scholarship and practice of clinical biochemistry. New Fellows will be honored during the NACB awards luncheon on Wednes-day, July 26.

The official Academy of AACC, NACB honors the achievements of its members, and through an active education and publication program, enlists their support and expertise to bring about positive change in the current practice of clinical biochemistry. To learn more about the Acad-emy and its activities, stop by the NACB desk in the AACC Booth (2051) or visit NACB’s Web site at www.nacb.org.

New NACB Fellows

Tito Bacarese-Hamilton, PhD Harold Harrison, MD, PhDLoring Bjornson, PhD That Ngo, PhDBonny Bukaveckas, PhD Maurice Owen, PhDDavid Bullock, PhD Richard Pang, PhDLeslie Burnett, MD, PhD Jagannadha Peela, MDOlukayode Dada, PhD Gurbuz Polat, MDMary Lou Gantzer, PhD Lori Sokoll, PhDAmit Ghoshal, PhD Andrea Terrell, PhDSorin Giju, PhD Young Wang, MD

Accepted since summer 2005.

Stop by the AACC Booth #2051

for the latest info on all our educational programs.

At AACC, we appreciate and value the dedication of our members and member volunteers who have significantly contributed to AACC’s growth and success over the decades. We are pleased to recognize members celebrating their 25 and 50 year anniversaries of continuous membership.

We are grateful to ALL our members, who through their worldwide leadership and dedication to the profession,continue to make AACC the premier organization for clinical laboratory scientists.

25 YEAR MEMBERS

Akira Abe

G. Robert Ainslie

Marilyn K. Barreca

Dennis Mark Bleile

William Z. Borer

Sheila Carol Boss

Jean-Pierre Braun

Michael D. Burke

Georges Chong

David Chou

Norman B. Coffman

Robert J. Cornette

Richard A. Cox

Joyce P. De Maio

Robert Farnham

William F. Fitter

Valerio M. Genta

Barbara J. Gillian

Frans K. Gorus

Christine Grudzien

Patricia A. Harper

Edward D. Helton

Richard Hoffman

Victor A. Hruszczyk

Judith Huse

Jean-Fritz Jean-Baptiste

Stanley C. Kammerer

Thais Edwina Keegan

David W. Kinniburgh

Henrietta L. Kohn

Mitchell Scott Laks

Dennis E. Leavelle

Douglas E. Lewis

Frank Ju-feng Liu

Ronald G. Markevitch

Samuel E. Mathews

Gina Micci

Alvine Mills

Michel H. Miron

Pei-Sheng Mo

David L Morris

Albert R. Nazareth

James Nielsen

Stephen Noel

Jose Maria Olivella Navarro

Barnabas H. Pataky

Linda S. Pellegrino

Penny I. Peng

Susan E. Puskas

Roberta G. Reed

Nader Rifai

Joe C. Rutledge

Ron B. Schifman

Frederick Alexandre Smith

Colen Bruce Smith

Wolfgang Stein

Galen G. Stickney

W. Allen Taylor

James L. Wittliff

Thomas E. Worthy

Randall W. Yatscoff

Jack Zakowski

50 YEAR MEMBERS

Samuel Frankel

S. Lawrence Jacobs

Gerald Kessler

Stanley Towers Lane

Theodore Peters

As of 4/22/2006


V A N S L Y K E F O U N D A T I O N ( V S F ) 2 0 0 5 H O N O R R O L LWe would like to recognize contributors who have made donations totaling $100 or more from January 1, 2005, through March 31, 2006. We also thank all of the donors to the VSF who have helped to fulfill our mission to advance clinical labora-tory medicine worldwide. For a current donor list, please go to http://www.aacc.org/vsf/honor_roll.stm.

C O R P O R A T E M E M B E R S

Leaders ($100,000 and more)Roche DiagnosticsOrtho Diagnostics Systems— Johnson & JohnsonAbbott Diagnostics

Patrons ($25,000 to $49,999)Beckman Coulter

Contributors ($10,000 to $24,999)Washington University of St. Louis

Subscribers ($5,000 to $9,999)International Federation of Clinical ChemistryDiagnostic Products Corporation

Donors ($100 to $4,999)Protedyne Corporation

AACC LOCAL SECTIONS & DIVISIONS

Sponsors ($10,000 to $49,999)TDM & Clinical Toxicology DivisionLipoproteins and Vascular Diseases Division

Sustainers ($5,000 to $9,999)Rocky Mountain Local SectionManagement Sciences Division

Patrons ($1,000 to $4,999)Capital Local SectionImmunology DivisionMichigan Local SectionMolecular Pathology DivisionPacific Northwest Local SectionSouthern California Local Section

Contributors ($100 to $999)Southeast Local Section

I N D I V I D U A L M E M B E R S

Leaders ($100,000 and more)Gopal SavjaniGerald and Sandy Gallwas

Sponsors ($10,000 to $49,999)Jocelyn HicksRichard NadeauBernard BrodyKerri WeinertRichard FlahertyRobert Habig

Sustainers ($5,000 to $9,999)Mary Lou GantzerLaurence DemersRobert Stout

Patrons ($1,000 to $4,999)Henry DiederichsCharles GalanaughJames LoWilliam OttingerBret WienMitchell ScottJan KrouwerBryce CunninghamThomas MoyerJohn SherwinFrederick BrazdaAnn GronowskiSalvador SenaEllis JacobsSusan EvansAnthony OkoroduduMathias MuellerBasil DoumasE. FreundJack TomasShirley Welch

Julius KerkayRoger CalamRoger BertholfWilliam LuftD. Robert DufourDonald PowersCipriano CiprianiNathan GochmanTsan LiuCarl GarberSara MichelmoreSteven WongSam BerkmanFred AppleMasashi ItanoAlan RunckMarion Mixson

Contributors ($100 to $999)Donald CannonJane SchwartzJean JosephHarold BrownKathleen CroesScott WilkinSidney TamJohn MasonClara SumeghyVijaykant KambliChristine PapadeaSusan GrossTheodore MifflinKatherine ChenJames RitchieOlive WolfeCarlotta EisenPeter TsivisKathleen QuillGeza Balas

Zheng ZengJean RhameEarl SoulesDaniel FarkasRuth McNairThomas YeungEnno LogemannBarbara CooperAnthony GirgentiHarold ChoitzHelen ChurellaBarry DowellStuart DubinWilliam FeldmanRichard LentThomas LiddyHoward LudwickDouglas StickleNathan RadinHarold WilliamsFumio YoshinoCheong NgoiJesse GoodwinRobert JohnsonMark MeyerhoffIrwin OreskesEugene GarciaSarah MookJohn RussoTerry Shirey Edward AshwoodHarald DrewsDalamaga AndronikiLuciano MarchettiSamuel MathewsHarvey KaufmanPhyllis FeinblumSpohia KakariCharles Hawker

Jean TraversWendy SakanoChing-Nan OuSally HojvatMichael BennettToshifumi NiwaLarry Broussard

Special GiftsThe Foundation extends special thanks to Mr. Gopal Savjani whose generous donation enabled the creation the Past Presidents’ Scholarship program. For further information about this new edu-cational opportunity go to www.aacc.org/vsf/past_pres_scholar-ship.stm.

The VSF also thanks Jerry and Sandy Gallwas for their gener-ous gifts, which fund multi-year AACC memberships for deserving scientists from emerging areas of the world to provide them with access to AACC program and services, see www.aacc.org/ia/gall-was.stm.

Planned Gifts The VSF gratefully acknowledges the following generous bequests from the following donors:Earl J. ScheragoBetty K. Smith

Contributions were made in memory of:Andrew Maturen, PhDDonald Soules, PhDHenry Weinert, PhDDonald Senn, PhD

ANIMAL CLINICAL CHEMISTRY DIVISION

Award for Outstanding Contributions To Animal Clinical ChemistrySponsored by Bayer DiagnosticsRecipient: Douglas J. Weiss, DUM, PhD, University of Minnesota, St. Paul, Minn.

CLINICAL & DIAGNOSTIC IMMUNOLOGY DIVISION

International Travel GrantRecipient: Dilshad Ahmad Khan Army Medical College, Wah, Pakistan

International Travel GrantRecipient: Sorin Giju Clinical Country Hospital Timisoara, Romania

Outstanding Research in Clinical and Diagnostic ImmunologyReducing autoantibody interference in thyroglobulin testing.Recipient: Andrew Hoofnagle, MD, PhD University of Washington, Seattle, Wash.

CRITICAL AND POINT-OF-CARE TESTING DIVISION

Point-of-Care Coordinator of the YearRecipient: Edwina F. Szelag Holmes Regional Medical Center— Health First, Inc, Melbourne, Fla.

Abstract Award WinnersOutstanding Research in Critical Care or Point-of-Care Testing The influence of prior oral anticoagulation

therapy on the activated clotting time. Recipient: S. El Rouby

Research Grant RecipientRole of alcohol induced liver damage on the regulation of vessel maturation.Recipient: Subir Kuman Das, PhD

HISTORY DIVISION

Sam Meites Award for Enhancing Our Knowledge of the History Of Clinical ChemistryRecipient: Louis Rosenfeld, PhD Brooklyn, N.Y.

INDUSTRY DIVISION

Industry Division Service AwardRecipient: To be announced

Best Abstract of Interest To the Industry DivisionRecipient: To be announced.

LIPOPROTEINS AND VASCULAR DISEASES DIVISION

Cooper Award for Outstanding Contributions to Service in the Area of Lipoproteins and Vascular DiseasesRecipient: G. Russell Warnick Berkeley Heart Lab, Alameda, Calif.

Pacific Biometrics Research Foundation Award for Contributions to the Technology of Clinical ChemistryRecipient: To be announced.

International Travel GrantRecipient: Dragana Begovic, KBC, Dr. Dragisa Misovic, Belgrade, Serbia & Montenegro

Outstanding Article in Fats of Life NewsletterRecipient: Jose Ordovas for “Gene-Diet In-teractions, Blood Lipids, and Cardiovascular Disease Risk: The Rise of Nutrigenetics.” Summer 2005, Fats of Life.

Poster Award WinnersThree awards are given for outstanding abstracts accepted at the AACC Annual Meeting in the area of lipoproteins and vascular diseases. Recipients are announced in Fats of Life.

MANAGEMENT SCIENCES DIVISION

Award for Outstanding Contributions to Management SciencesRecipient: Carl Garber, PhD, Quest Diagnostics, Lyndhurst, N.J.

International Travel GrantRecipient: Shivananda Nayak, Eric Williams Medical Science Complex, Mount Hope, Trinidad & Tobago.

MOLECULAR PATHOLOGY DIVISION

Outstanding Research in the Area of Molecular Pathology Or Pharmacogenomics

Simultaneous determination of seven N-acetyltransferase -2 polymorphisms by allele-specifc primer extension assay.Recipient: Ysheng Zhu

Young Investigator Award for Outstanding Research in Molecular Pathology or PharmacogenomicsCorrelation of venous and capillary trough and C-2 cyclosporin A concentrations by ILC/MS/MS with CYP3A4* and CYP3A5*3 geotypes in transplant patients.Recipient: Paul Janetto, PhD

NUTRITION DIVISION

Gary Labbe Award for Contributions to Laboratory Assessment of Nutritional StatusRecipient: To be announced.

PEDIATRIC & MATERNAL-FETAL DIVISION

Award for Outstanding Contributions to Pediatric and Maternal-Fetal Clinical ChemistryRecipient: George Brotea, PhD Ortho-Clinical Diagnostics, Inc., Rochester, N.Y.

THERAPEUTIC DRUG MONITORING & CLINICAL TOXICOLOGY DIVISION

TDM/Toxicology Young Investigator AwardRecipient: To be announced.

AACC Divisions Recognize Contributions to Laboratory MedicineAACC’s divisions routinely recognize the achievements and contributions of their colleagues through awards and travel grants. Congratulations to these award winners for 2006.

Clinical LaboratoryNews

EDITORIAL STAFF

Editor—Nancy Sasavage, PhD

Senior Editors—Julie McDowell and Richard Pizzi

Managing Editor—Bill Malone

Contributor—George Linzer

BUSINESS STAFF

V.P. Marketing Programs—Jerry Goldsmith

Circulation Manager—Mickie Napoleoni

BOARD OF EDITORS

Chair—Steve Manzella, PhD, York Hospital, York, Pa.

Members—Janine M. Cisek, MT(ASCP), St. Luke’s Hospital, Kansas City, Mo.

Thomas Daly, MD, Eli Lilly and Company, Indianapolis, Ind.

David Grenache, PhD, University of North Carolina at Chapel Hill, Chapel Hill, N.C.

Jack A. Maggiore, PhD, BioSafe Laboratories, Chicago, Ill.

Alan T. Remaley, MD, PhD, National Institutes of Health, Bethesda, Md.

AACC OFFICERS

President—John E. Sherwin, PhD

President-Elect—Gary L. Myers, PhD

Treasurer—Larry A. Broussard, PhD

Secretary—Robert L. Murray, JDS, PhD

Past-President—Mitchell G. Scott, PhD

ADVERTISING SALES

Scherago International, Inc. 525 Washington Blvd., Suite 3310 Jersey City, NJ 07310. Phone: (201) 653-4777. Fax: (201) 653-5705. E-mail: [email protected].

President—H.L. Burklund

Vice President Sales—Jack Ryan

Marketing Director—Steven A. Hamburger

Traffic Manager—Olga Guerra

SUBSCRIPTIONS

American Association for Clinical Chemistry, Inc. 1850 K Street, NW, Suite 625, Washington, DC 20006. Phone: (202) 857-0717 or (800) 892-1400. Fax: (202) 887-5093. E-mail: [email protected].

Subscriptions to Clinical Laboratory News are free to qualified laboratory professionals in the United States. AACC members outside the U.S. pay $60 for postage. The subscription price for those who do not qualify for a free subscription is $60/year in the U.S. and $95/year outside the U.S. Back issues may be ordered for $10 as available. For more information, contact the AACC Customer Service Department at (800) 892-1400 or (202) 857-0717 or [email protected].

EDITORIAL CORRESPONDENCE

Nancy Sasavage, PhD, Editor Clinical Laboratory News, 1850 K Street, NW, Suite 625, Washington, DC 20006. Phone: (202) 857-0717 or (800) 892-1400. Fax: (202) 835-8725. E-mail: [email protected].

Contents copyright © 2006 by the American Association for Clinical Chemistry, Inc., except as noted. Printed in the U.S.A.

Clinical Laboratory News (ISSN 0161-9640) is the authoritative source for timely anal-ysis of issues and trends affecting clinical laboratories, clinical laboratorians, and the practice of clinical laboratory science.


P L E N A R Y S P E A K E R S P O T L I G H T

Douglas C. Wallace, PhDMitochondria: The Missing Link Among Degenerative Diseases, Cancer and Aging, and the Next Molecular Diagnostics FrontierThursday, July 27, 12:30–2:00 p.m.

Current Position: Donald Bren Professor of Molecular Genetics, Department of Ecology and Evolutionary Biology, University of California, Irvine (UCI); Director, Center for Molecular & Mitochondrial Medicine and Genetics (MAMMAG), UCI.

Education: Yale University—PhD, 1975.

Previous Positions: Robert W. Woodruff Professor of Molecular Genetics and Director of the Center for Molecular Medicine, Emory University; Professor of Genetics, Stanford University School of Medicine.

A Founder of Mitochondrial Genetics

One of the world’s leading scientists whose work ranges from tracing the origins of the human species to finding the causes of de-generative diseases, cancer and aging, Doug-las Wallace, PhD, is one of the founders of the field of human mitochondrial genetics. Cur-rently the Donald Bren Professor of Molecu-lar Genetics at the University of California, Irvine, and director of the university’s Cen-ter for Molecular and Mitochondrial Medi-cine and Genetics (MAMMAG), Wallace’s pioneering research has bridged the fields of microbiology, human genetics, medicine, and anthropology.

In the early 1970s, Wallace demonstrated that mitochondrial DNA (mtDNA) muta-tions can cause certain forms of diabetes, car-diac and muscle disease, blindness, deafness, seizures, movement disorders, and demen-tias. He has shown that mtDNA mutations accumulate in our tissues with age, and thus

may be the key to the degenerative aspects of aging. In studying mitochondrial genetic evolution, Wallace’s research group used mtDNA variation to reconstruct the origins and ancient migrations of women, and de-termined that all mtDNA lineages trace back to a single African origin some 200,000 years ago. His “mitochondrial Eve” theory has been a foundation of the new field of molecular anthropology and is hailed as a significant achievement in paleoanthropology.

And there are other practical applications for Wallace’s work still on the horizon. Medi-cations currently under development in his MAMMAG lab—called catalytic antioxi-dants—may someday help mitigate damage done to the mitochondria when mtDNA mutations accumulate.

A member of the National Academy of Sciences, in 1994 Wallace received the Wil-liam Allan Award, the American Society of Human Genetics’ highest recognition for

contributions to human genetics. He also shared the Passano Award 2000 for mito-chondrial genetics and received the 2000 Metropolitan Life Foundation Research Award for Medical Research in Alzheimer’s Disease.

Wallace’s mitochondrial research has fostered the exploration of the relationship between human evolution and some of the most common and disabling diseases. In his plenary lecture, Wallace will explain how the degenerative effects of aging may largely be fueled by accumulated mitochondrial muta-tions and the resulting malfunction of or-gans and systems throughout the body. He will also illustrate how many mtDNA mal-functions have their roots in evolutionary adaptations hidden in the history of the hu-man species, and describe the ways in which mitochondrial research can lead to further understanding of major diseases. CLN

Thursday’s Plenary Speaker,Douglas C. Wallace, PhD

William R. Clarke, MDThe Convergence of Diagnostics and the Transformation of MedicineWednesday, July 26, 8:45–10:15 a.m.

Current Position: Executive Vice President, Chief Medical and Technology Officer, GE Healthcare (Waukesha, Wis.)

Education: Duke University, Durham, N.C.—MD, MS, 1979; BA, 1974.

Previous Positions: Executive Vice President, Research and Development, Amersham Health; Director of Biological Sciences, Glaxo Wellcome U.K.; Associate Professor, Department of Anesthesiology/Critical Care Medicine and Pediatrics, University of Washington School of Medicine.

Emphasizing Molecular Diagnostics And Disease Prevention

In his current position as Executive Vice President at GE Healthcare (Waukesha, Wis.), William R. Clarke, MD, oversees a global technology and medical innovation portfolio with an average annual budget of approximately $1 billion. He also directs medical and regulatory strategy and policy for GE Healthcare and sits on the company’s Executive Committee. Diagnostic technolo-gies are at the center of GE Healthcare’s new “early health” model of care, which focuses on earlier diagnosis, pre-symptomatic dis-ease detection, and disease prevention, and that makes Clarke ideally suited to convey the importance of molecular diagnostics to the future of medical care.

Before joining GE Healthcare in April 2004, Clarke was the head of Global Research and Development at Amersham Health (Buckinghamshire, U.K.), where he managed

a staff of 925 and administered an annual budget in excess of $145 million. His multi-national R&D division supervised all aspects of pharmaceutical discovery, development, registration, and post-market support for Amersham. Clarke was Amersham’s lead spokesperson in multiple forums that ad-dressed the impact of the new generation of molecular diagnostics on medical practice.

Prior to his tenure at Amersham, Clarke spent three years as Director of Biological Sciences at Glaxo Wellcome U.K. (Uxbridge, U.K.), with responsibility for pre-clinical disease-focused biological research. He also chaired the Glaxo Wellcome Global Imaging Strategy Committee, which formulated cor-porate strategy and developed partnerships between industry and government.

Before his time in industry, Clarke spent more than fifteen years in the academic world as a practicing academic physician with a specialty in pediatric critical care and

pediatric anesthesiology. He also has re-search interests in pulmonary pharmacology and genetics. Clarke’s most recent academic appointment was as Associate Professor in the Departments of Anesthesiology/Critical Care Medicine and Pediatrics at the Univer-sity of Washington School of Medicine.

Clarke received his BA in Chemistry, MS in Physiology and Pharmacology, and MD from Duke University (Durham, N.C.). He was also educated at the University of Wash-ington School of Medicine, the University of Pennsylvania, and the Stockholm School of Economics.

In his plenary lecture, Clarke will explain the role that molecular in vitro diagnostics play in directing clinicians towards the effec-tive use of highly specific in vivo molecular imaging diagnostics. He will also highlight the convergence of in vivo and in vitro diagnos-tics with new targeted therapies in relevant clinical disciplines such as oncology. CLN

Wednesday’s Plenary Speaker,William R. Clarke, MD


AACC expresses its gratitude to the Annual Meeting

Organizing Committee (AMOC) for its hard work in putting together another ex-ceptional meeting. The AMOC has spent the past 18 months planning and organiz-ing an exciting program featuring a num-ber of new session formats—all designed to provide attendees the type of learning environment that provides the best edu-cational experience. In addition to five outstanding Plenaries, this year’s program offers half-day and full-day Symposia, tru-ly Interactive Workshops, Short Courses, and early morning and noontime Brown Bag sessions for small group discussions.

New for 2006 are sessions called “Meet the Experts”—seven sessions that feature interactive discussions with the plenary speakers and other invited experts in the field, and two Chair’s Invited Sessions or-ganized by AMOC Chair Dr. Daniel Farkas —lab workforce issues and lab medicine in the consumer environment.

And don’t forget, please turn in the ACCENT evaluation forms at each session you attend.

2 0 0 6 A N N U A L M E E T I N G

Welcome to the 2006 Clinical Laboratory ExpositionAACC and ASCLS welcome you to the 2006 Clinical Lab Expo. Once again, the Expo has broken previous records for number of exhibitors and number of booths, with more than 700 exhibitors in more than 1,700 booths. While you are visiting the exhibit hall, don’t forget to check out the more than 800 posters that will be presented in groups during exhibit hours.

You will want to plan your time carefully to make sure that you see the exhibitors that offer the products and services you are looking for. The product locator terminals in the registration area can help you plan your exposition time. We also encourage you to use your expo visit time today to walk around and make appointments for later in the week—the exhibitors will have more time for one-on-one discussions on Wednesday and Thursday. Also, note that exhibit hours for Thursday have been changed. Exhibits will open at 8:30 a.m. and close at 2:00 p.m. We wish you a very successful and enjoyable visit to the 2006 Annual Meeting.

Thanks to the Annual Meeting Organizing Committee

2007July 15–19

San Diego, Calif.

2008July 27–31

Washington, D.C.

2009July 19–23Chicago, Ill.

Future AACC Annual Meetings

2006 Annual Meeting Organizing CommitteeChair—Daniel H. Farkas, PhD, HCLD, Chondrogene, Inc., Toronto, CanadaVice-Chairs—Thomas Annesley, PhD, University of Michigan, Ann Arbor, Mich. Stephen Kahn, PhD, Loyola University Medical Center, Maywood, Ill.Symposia Coordinators—Andrea Ferreira-Gonzalez, PhD, Medical College of Virginia, Richmond, Va.; Rogerio Rabelo, MD, PhD, Fleury Diagnostics, São Paulo, BrazilWorkshop/Short Course Coordinators—Marcy Anderson, PhD, Medical Automation Systems, Charlottesville, Va.; Kenneth Bahk, PhD, Nanosphere, Inc., Northbrook, Ill.Brown Bag Coordinator—Joan Gordon, Maine Molecular QC, Inc., Scarborough, MaineAbstracts Coordinator—Kristen Skogerboe, PhD, Seattle University, Seattle, Wash.Volunteer Coordinator—Deanna Klosinski, PhD, Petoskey, Mich.Staff—Gail Mutnik, MPA, AACC, Washington, D.C.

HOURSRegistration

McCormick Place Convention Center

Saturday, July 22 12 noon – 5:00 p.m.

Sunday, July 23 8:00 a.m. – 6:30 p.m.

Monday, July 24 7:00 a.m. – 5:00 p.m.

Tuesday, July 25 7:00 a.m. – 5:00 p.m.

Wednesday, July 26 7:00 a.m. – 5:00 p.m.

Thursday, July 27 8:00 a.m. – 4:00 p.m.

Clinical Lab ExpoThe AACC Booth (#2051 on the exhibit floor) will be open during exposition hours.




AACC BookstoreAcross from the Registration Area.

Sunday, July 23 9:00 a.m. – 5:00 p.m.

Monday, July 24 9:00 a.m. – 5:00 p.m.




Plenary Sessions

Sunday, July 23 5:00 p.m. – 6:30 p.m.

Monday, July 24 8:45 a.m. – 10:15 a.m.

Tuesday, July 25 8:45 a.m. – 10:15 a.m.

Wednesday, July 26 8:45 a.m. – 10:15 a.m.

Thursday, July 27 12:30 p.m. – 2:00 p.m.

Interactive Workshops and Short Courses

Sunday, July 23 10:30 a.m. – 12 noon

1:30 p.m. – 4:00 p.m.

Monday, July 24 10:30 a.m. – 12 noon

2:30 p.m. – 5:00 p.m.

Tuesday, July 25 10:30 a.m. – 12 noon

2:30 p.m. – 5:00 p.m.

Wednesday, July 26 10:30 a.m. – 12 noon

2:30 p.m. – 5:00 p.m.

Brown Bag Sessions

Monday, July 24 7:30 a.m. – 8:30 a.m.

12:30 p.m. – 1:30 p.m.

Tuesday, July 25 7:30 a.m. – 8:30 a.m.

12:30 p.m. – 1:30 p.m.

Wednesday, July 26 7:30 a.m. – 8:30 a.m.

12:30 p.m. – 1:30 p.m.

For information on other sessions, please see the program guide.

July 25-27, 2006 Chicago, IL


EDITORIAL STAFF




BUSINESS STAFF



BOARD OF EDITORS







AACC OFFICERS






ADVERTISING SALES






SUBSCRIPTIONS








Leonard Quadracci, MDEmployer-Managed Healthcare: Corporations Get Back into the Healthcare BusinessTuesday, July 25, 8:45–10:15 a.m. Current Position: President, QuadMed, LLC and QuadMed Corporate Health Services (West Allis, Wis.)

Education: Marquette University Medical School (now Medical College of Wisconsin, Milwaukee), MD

Previous Positions: Faculty of University of Washington School of Medicine; Internal medicine practice in Bellevue, Wash.

Managing Health Care in the Corporate WorldFor more than 35 years, Leonard Quadracci, MD, has been practicing medicine and di-recting health care services as the President of QuadMed, LLC, and QuadMed Corporate Health Services. Since joining the company in 1995, he has directed health care man-agement for Quad/Graphics, a commercial printer based in Sussex, Wisconsin. While fo-cusing on the quality, accessibility, and afford-ability of medical care for Quad/Graphics’ 12,000 employees, Quadracci has also em-phasized wellness and preventive care, and has enabled the company to keep rising health care costs in check. For example, Quad/Graphics pays 20 percent less than the average Wisconsin employer for employee medical costs.

During his tenure with QuadMed and Quad/Graphics, Quadracci has overseen the

substantial expansion of Quad/Graphics’ on-site medical facilities, which now num-ber four. In his role as President of Quad-Med, he oversees a staff of 240—including 40 physicians and other medical providers. In addition, he practices internal medicine and specializes in nephrology, the study of the kidney and its functions. As President of QuadMed Corporate Health Services, Quadracci oversees a variety of corporate health care services, including health care clinic management and occupational medi-cine services such as executive physicals and pre-employment screenings. In addition, he currently oversees the management of health care clinics for Miller Brewing Co. and Briggs & Stratton.

A graduate of Marquette University and the Marquette University Medical School (now the Medical College of Wisconsin)

in Milwaukee, Quadracci spent more than 20 years on the faculty of the University of Washington School of Medicine in Seattle, where he ultimately became an Associate Professor of Medicine and Pathology before joining QuadMed. In addition, he practiced internal medicine for 18 years in Bellevue, Wash. He also established the Lake Washing-ton Kidney Center in Bellevue in 1981 and served as its medical director for 15 years.

For his plenary talk, “Employer-Managed Healthcare: Corporations Get Back into the Healthcare Business,” Quadracci will speak about the evolution of the QuadMed pro-gram, including why the company decided to bring laboratory services in-house and the implications of that move, as well as what he believes are the important factors that improve quality and control costs in health care. CLN

Tuesday’s Plenary Speaker,Leonard Quadracci, MD


Edwina Szelag Selected as 2006 Point-of-Care Coordinator of the Year

AACC’s Critical and Point-of-Care Testing Division honors the contributions of point-of-care coordinators to excellence in health care through its Point-of-Care Coordinator of the Year program. This year the honor goes to Edwina Szelag from Holmes Regional Medical Center—Health First, Inc. in Melbourne, Fla.

As POCT Coordinator for Health First, a three-hospital integrated health care delivery system in Brevard County Florida, Ms. Szelag is responsible for leading and implementing initiatives that focus on performance improvement, quality assurance, communication, and education and accreditation compliance relating to

POCT. The Health First system includes Holmes Regional Medical Center, Palm Bay Community Hospital, and Cape Canaveral Hospital. Services and specialties include women’s and children’s, outpatient centers for surgery, endoscopies, wound care, pain management, diabetes, home care, hospice, cancer, heart, stroke, and rehabilitative services. In addition, the system is also home to the county’s only trauma center and “Vital Watch,” or eICU. Under her guidance, the organization continues to be accredited for all bedside testing under CAP and JCAHO. Not only has the organization grown, but the POCT program has also expanded. In 1996, Health First POCT consisted of five different POCT tests; today it oversees 11 different test methods, over 1,700 operators, and volumes have grown exponentially.

Ms. Szelag earned her Bachelor of Science degree in Medical Technology from Quinnipiac College in Connecticut. As a student intern in Yale’s School of Medicine Medical Technology Program, she worked in the clinical chemistry department at Yale New Haven Hospital. Upon relocation to Florida, she worked as a technologist in the blood bank at Plantation General Hospital in Plantation Florida and then became a senior technologist in hematology and coagulation at Broward General Medical Center in Fort Lauderdale, Fla. Prior to moving to Melbourne, she earned her Masters in Health Management from St. Thomas University in Miami. She joined the staff of Holmes Regional Medical Center in 1990, where she has held positions as a senior technologist in hematology and as senior technologist over the laboratory’s STAT Lab.

In 1995, Ms. Szelag became the assistant in laboratory administration for quality assurance and began to work with a bedside testing program still in its infancy. Her impact on improving the quality and safety of the POCT program has been far-reaching across the system and is best illustrated by her active participation and outstanding contributions in several continuum of care and performance improvement teams at all three hospitals, as well as the corporate level. Her program involves representatives from all areas involved in testing, and each is trained to the knowledge and standards expected for POCT. Regular meetings as well as newsletters and electronic-based testing modules help to keep communication and com-petency on the forefront. Ms. Szelag also remains an active instructor at new associate orientation, skill fairs, and a monthly adult diabetes support group. She continues to dedicate herself to defining best practices for POCT, and as such, has become a strong leader in the POCT community.

In addition to forming and supervising the POCT program at Health First, Ms. Szelag has also been instrumental in creat-ing the Florida East Coast Point-of-Care Testing Coordinators Conference which has been held each fall in Cocoa Beach, Fla. since 2000. In 2003, along with the support of other POCCs in the Central Florida area, this conference merged into the “Cen-tral Florida POC Network”. She is Co-Chair of this group, which was also responsible for hosting the recent “AfterGlow” event enjoyed by hundreds of POCCs in attendance at the AACC Annual Meeting held last year in Orlando. She continues to be a speaker at local, state, and national educational seminars on POCT topics, including implementation of critical care programs for POCT and issues in compliance.

This auspicious award, sponsored by the AACC CPOCT Division and funded by Lifescan, Inc., includes a cash award, fund-ing to attend the AACC Annual Meeting, and an elegant trophy. The award will be presented at the CPOCT Division Mixer on Tuesday, July 25, 6–8 p.m., at the Hyatt Regency Chicago Hotel.


INDEX TO ADVERTISERSPlease thank these advertisers by telling them you saw their

advertisement in Clinical Laboratory News

Alifax S.P.A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48

Antek HealthWare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32

Artel Corporation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28

Bayer HealthCare, Diagnostics Division . . . . . . . . . . . . . . . . . . . . . . . . 52

BD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36

Bio-Rad Laboratories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25, 33

Biosite Incorporated . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23, 35

College of American Pathologists . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30

Diamedix Corporation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37

DRG International, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14

Eppendorf AG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45, 47, 49

Eppendorf, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 (insert), 11, 13

INOVA Diagnostics, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39

Invetech Pty Ltd . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22

LifeScan, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 & 5

Medical Laboratory Evaluation (MLE) . . . . . . . . . . . . . . . . . . . . . . . . . 22

Midland Bioproducts Corporation . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18

Olympus America, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2

Ortho-Clinical Diagnostics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17, 19, 21

Precision Systems, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18

Protedyne . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34

Quest Diagnostics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7

Randox Laboratories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31

Roche Diagnostics Corporation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27

Scantibodies Laboratory, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26

Sysmex America, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29

Utak Laboratories, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20

Waters Corporation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24

OEMFluid Metering, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43

KMC Systems, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40

Michigan Diagnostics, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42

Millipore Corporation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38

Oyster Bay Pump Works, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41

ZeptoMetrix Corporation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42

Tuesday, July 25, 10:00 a.m. A-27Jacoline Brinkman Cystatin C is a predictor of cardiovascular morbidity and mortality independent of renal function and other cardiovascular risk factors.

Tuesday, July 25, 10:00 a.m. A-87Jasper Remijn Novel molecular defect in the platelet ADP receptor P2Y12 in a patient with a history of unexplained severe congenital bleeding.

Tuesday, July 25, 2:00 p.m. B-18Ronald Pang Serum proteomic profiling identified beta-thromboglobulin and platelet factor 4 as prognostic indicators in severe acute respira-tory syndrome.

Tuesday, July 25, 2:00 p.m. B-64Yusheng Zhu, PhDGenotyping of VKROC1 polymorphisms (-1639G>A) for patients on Warfarin therapy using allele-specific primer extension assay.

Wednesday, July 26, 10:00 a.m. C-111Irina Kirpich Free fatty acid composition of blood serum in patients with acute alcoholic psychosis.

Wednesday, July 26, 2:00 p.m. D-3Fred Apple, PhDMultibiomarker profiling for detection of adverse events in acute coronary syndrome patients.

Wednesday, July 26, 2:00 p.m. D-21David Gaze Oxidised low-density lipoprotein (ox-LDL)

is a poor short-term event marker in acute coronary syndrome patients who present to the emergency department.

Wednesday, July 26, 2:00 p.m. D-44Qing Meng, PhD, MDThe protective role of hydrogen sulfide in the pathogenesis of atherosclerosis.

Wednesday, July 26, 2:00 p.m. D-52David Pritchard, PhDActivated Factor XII Type A strongly predicts all cause mortality after hospitalization with chest pain.

Thursday, July 27, 9:00 a.m. E-4Romolo Dorizzi, MDDiagnostic odds ratios of different S-100 B protein concentrations in the follow-up of malignant melanoma.

Thursday, July 27, 9:00 a.m. E-19Shu-Ling Liang, PhDA pharmacoproteomic approach to evalu-ate the effects of an epidermal growth factor receptor inhibitor on tumor tissues.

Thursday, July 27, 9:00 a.m. E-24Rama Mittal, PhDInter-relationship between prostate specific antigen, kallikrein-2 and androgen receptor gene polymorphisms with risk of prostate cancer in India.

Thursday, July 27, 9:00 a.m. E-77Brad Karon, PhD, MDMonitoring glucose concentration in patients on intensive intravenous insulin therapy.

The National Academy of Clinical BiochemistryThe Academy of AACC

2006 NACB Distinguished Abstract Awards

The NACB is proud to announce the following recipients of its 2006 Distinguished Abstract Awards. This Academy program is designed to recognize scientific excellence among abstracts accepted for presenta-tion at the AACC 2006 Annual Meeting. The following 13 abstracts were chosen from 629 abstracts accepted for presentation at the meeting.

A rigorous selection process is used that incorporates a primary review by AACC members followed by a second review performed by a group of NACB Fellows. Only those abstracts that meet strict criteria during both reviews are designated as Distinguished Abstracts.

BY LINNEA M. BAUDHUIN, PHDChair, SYCL

AACC’s Society for Young Clinical Laboratorians (SYCL) marks its two-year anniversary this week. Created in 2004 to meet the needs of AACC’s young and student members, our mission is to develop programs that sup-port and encourage career development in the clinical laboratory sciences. Membership in SYCL is automatic for individuals who are under 40 years of age or who are registered as a student member of AACC. You can easily

spot SYCL members by the logo stickers on their badges.Here in Chicago, SYCL has organized two special events. Following the

Monday afternoon student poster contest, we are hosting a networking reception for SYCL members and AACC leaders. On Thursday morning, from 9:30 a.m. to 12:00 p.m., all are invited to a free SYCL-organized symposium entitled “Making Sense of the Alphabet Soup of Laboratory Regulations,” which will provide attendees with a better understanding of the numerous regulatory and accreditation requirements for clinical laboratories.

In addition our existing programs, SYCL is introducing some new activi-ties aimed at supporting young clinical laboratorians. For example, we were pleased to support this year’s inaugural winners of the SYCL Domes-tic Travel Grant: Christopher McCudden, from Duke University Medical

Center (Raleigh, N.C.), and Alagarraju Muthukumar, from the University of Texas Southwestern Medical Center (Dallas, Texas). This grant was funded by the Van Slyke Foundation and supported in part by the Foundation for BD Diagnostics. To aid junior clinical laboratory profession-als in employment negotiations, we have also updated our Web site with tips and questions to ask potential employers, and we are developing an employment and salary survey. And soon to be posted on our Web site, updated tips and information for laboratorians who are preparing for the American Board of Clinical Chemistry certification exam.

The SYCL Seminar Series (SSS), designed to promote clinical laboratory science as a career to young scientists, was a huge success last year thanks to our fantastic speakers: Niki Baumann, William Clarke, David Colantonio, Corrine Fantz, and Carmen Wiley. Now in its second year, the SSS is hoping to continue its success with promotion by these outstanding SYCL mem-bers: Joshua Bornhorst, Bonnie Bukavecas, Shannon Haymond, Alex Rai, Kristin Reynolds, Amy Saenger, and Jennifer Snyder.

2007 looks to be an equally exciting and active year for SYCL. We plan to continue the Mentor of the Month and SYCL Seminar Series, update and make additions to the SYCL Web site, and promote events at the AACC An-nual Meeting.

For more information, please visit our Web site at www.aacc.org/sycl.

Happy Second Anniversary The Society for Young Clinical Laboratorians


I N D U S T R Y W O R K S H O P S

TUESDAY, JULY 25

7:00am–8:30am

ABBOTT LABORATORIESFairmont Hotel, Gold RoomLaboratory Automation: Process Improvement Through a Family of Integrated AnalyzersSpeakers: Pennell Painter, PhD, FACB, Dynacare Tennessee Laboratory, University of Tennessee Medical CenterMichael J. Nicar, PhD, Baylor University Medical CenterGary S. Assarian, DO, FACP, Hospital Consolidated Laboratory, Southfield, Mich.

ABBOTT LABORATORIESFairmont Hotel, International BallroomNew Markers in Laboratory MedicineSpeakers: Ravi Thadhani, MD, MPH, Harvard Medical SchoolPrasad Devarajan, MD, Cincinnati Children’s Hospital Medical Center, University of CincinnatiOscar Segurado, MD, PhD, Abbott Immunology

BECKMAN COULTER, INC.Hyatt Hotel, Columbus Hall IJAutomation: Selling It to the Board—Administrative Director View (Part 1)Speakers: Judy Darr, Pinnacle Health HospitalsDoug Schreffer, Pinnacle Health Hospitals

BECKMAN COULTER, INC.Hyatt Hotel, Columbus Hall KLImpact of Preanalytical Error on Immunoassay ResultsSpeakers: Sheila Hanna, PhD, Beckman Coulter, Inc.Nancy Dubrowny, MS, MT(ASCP)Sc, Beckman Coulter, Inc.

BIO-RAD LABORATORIESFairmont Hotel, Imperial RoomThe Clinical Utility of A1C Testing for the Diabetic Patient & Method SelectionSpeakers: David Sacks, MD, Brigham and Women’s HospitalAlvin Michael Spiekerman, PhD, Texas A&M Medical SchoolTrefor Higgins, MSc, Dynacare Kaspar Medical Laboratories, Alberta

DIAGNOSTIC PRODUCTS CORPORATION Hyatt Regency Chicago, Regency Ballroom A Interpreting NT-proBNP Results in Acute and Primary Care SettingsSpeakers: Paul O. Collinson, MD, FRCPath, FACB St. George’s Hospital and Medical school, U.K.

HYTEST LTD./INNOTRAC DIAGNOSTICSFairmont Hotel, State RoomEarly Cardiac Triage in the Troponin EraSpeakers: Fred S. Apple, PhD, DABCC, Hennepin County Medical CenterAlexei Katrukha, PhD, HyTest Ltd.Kim Pettersson, PhD, Univ. of Turku, FinlandSusann Eriksson, PhD, Univ. of Turku, FinlandQiu-Ping Qin, PhD, MD, Univ. of Turku, FinlandSaara Wittfooth, MSc, Univ. of Turku, Finland

ORTHO-CLINICAL DIAGNOSTICSHyatt Regency Chicago, Regency Ballroom BDo You Know What You are Paying For? How Four Laboratories Used 21st Century Metrics to Find OutSpeakers: Jacqueline Vealey, MT (ASCP) SH, Ortho-Clinical DiagnosticsMaureen Harte, MT(ASCP), Ortho-Clinical DiagnosticsOther speakers TBD

MILLENIA DIAGNOSTICS, INC.Fairmont Hotel, Regent RoomEmerging Technologies in Rapid DiagnosticsSpeakers: Danny Levenson, BS, Millenia Diagnostics, Inc.Ryan Knoth, BS, Millenia Diagnostics, Inc.Bill Doering, PhD, Oxonica, Inc.

ROCHE DIAGNOSTICS CORP.Fairmont Hotel, Crystal RoomA Molecular Laboratory StartupSpeakers: Bryan Moore, PhD, Roche DiagnosticsScott Sargent, Roche Diagnostics

ROCHE DIAGNOSTICS CORP.Hyatt Regency Chicago, Grand Ballroom BLean—It’s a Lifestyle not a DietSpeakers: Caroline Ambrose, MT(ASCP), CQM(ASQ), Healthcare SolutionsAnne Daley, MS, MT(ASCP), DLM, Healthcare Solutions

ROCHE DIAGNOSTICS CORP.Hyatt Regency Chicago, Grand Ballroom ANatriuretic Peptides— Clearing the ConfusionSpeakers: Robert H. Christenson, PhD, University of Maryland Medical centerChristopher deFillipi, MD, University of Maryland School of MedicinePaul Collinson, MD, PhD, St. George’s University Teaching Hospital, U.K.

SERADYN, INC.Fairmont Hotel, Moulin RougeQMS® Lamotrigene Immunoassay: The First Available Immunoassay for the Quantitative Determination of Lamotri-gene Levels in Human Serum or PlasmaSpeakers: Mark Roberts, PhD, Seradyn, Inc.Lili Arabshahi, PhD, Seradyn, Inc.Melissa Wall, BS, Seradyn, Inc.

TUESDAY, JULY 25

6:00pm–7:30pm

ABBOTT LABORATORIESFairmont Hotel, Gold RoomImmunoflowcytometry in Routine HematologySpeakers: Richard Kimball, PhD, Abbott HematologyBruce Davis, MD, Trillium Diagnostics, LLC

APPLIED BIOSYSTEMSHyatt Regency Chicago, Regency Ballroom AIntroduction to LC/MS/MS for Clinical ResearchSpeaker: Michael Baynham, PhD, Applied Biosystems

CENTERCHEM, INC./PENTAPHARM, LTD.Hyatt Regency Chicago, Grand Ballroom AAnticoagulant Monitoring with Pefakit® PiCT®Speaker: Dorothy Adcock, MD, Esoterix Coagulation-LabCorp

COHESIVE TECHNOLOGIES INC.Hyatt Regency Chicago, Grand Ballroom BOvercoming Sample Preparation Bottlenecks and the High Cost Associated with Tandem Mass Spectroscopy for Validated Clinical Diagnostic AssaysSpeakers: Jean M. Lacey, Mayo ClinicPierre Marquet, PhD, University Hospital of Limoges, FranceJoseph DiBussolo, PhD, University of West Chester

DAVID G. RHOADS ASSOCIATES, INC.Fairmont Hotel, Regent RoomEstablishing Performance Standards for Clinical Laboratory InstrumentsSpeaker: David G. Rhoads, PhD, DABCC, David G. Rhoads Associates, Inc.

DIAGNOSTIC PRODUCTS CORPORATIONHyatt Regency Chicago, Regency Ballroom BDealing with Common QC ProblemsSpeakers: Jim Aguanno, PhD, Diagnostic Products CorporationNils Person, PhD, Diagnostic Products CorporationMark Smith, Diagnostic Products Corporation

ILLUMINAFairmont Hotel, State RoomComprehensive Coverage: Illumina’s Digital Microbead Array TechnologySpeaker: David Barker, PhD, Illumina

IRIS DIAGNOSTICS, INC.Fairmont Hotel, Imperial BallroomEmergence of Wet Diagnostic Urinalysis and the Clinical Value of Body Fluid Cell CountsSpeaker: G. Barry Schumann, MD, Schumann Diagnostics, University of PennsylvaniaNancy Bruneel, MS, CLS (NCA), University of Minnesota

ROCHE DIAGNOSTICS CORP.Fairmont Hotel, Crystal RoomAmpliChip CYP450 Testing: Going ClinicalSpeakers: Zixuan Wang, PhD, MDxBrigitte Fernandez-McAlear, Roche Diagnostics

ROCHE DIAGNOSTICS CORP.Fairmont Hotel, Moulin RougeUnderstanding Evidence Based Outcomes of Automation with a Single Solution from Roche DiagnosticsSpeakers: TBD

TM BIOSCIENCE CORPORATIONFairmont Hotel, International BallroomPharmacogenetic Testing in the Clinical SettingSpeakers: TBD

WEDNESDAY, JULY 26

7:00am–8:30am

ABBOTT LABORATORIESFairmont Hotel, International BallroomThe Impact of Cardiac Biomarkers on Clinical PracticeSpeakers: Fred S. Apple, PhD, DABCC, Hennepin County Medical CenterPer Venge, MD, PhD, University Hospital, Uppsala, SwedenStanley L. Hazen, MD, PhD, Cleveland ClinicAlan H.B. Wu, PhD, University of California, San Francisco

APPLIED BIOSYSTEMSHyatt Regency Chicago, Regency Ballroom AThe Use of Tandem Mass Spectrometry in Clinical Research: Technology and ApplicationsSpeaker: Michael Baynham, PhD, Applied Biosystems

BECKMAN COULTER, INC.Hyatt Hotel, Crystal Ballroom AAutomation: Making It Happen— Lab Operations Director View (Part 2)Speakers: Judy Darr, Pinnacle Health HospitalsDoug Schreffer, Pinnacle Health Hospitals

BECKMAN COULTER, INC.Hyatt Hotel, Crystal Ballroom B False Positive Cardiac Troponins: True or FalseSpeakers: Bernard C. Cook, PhD, DABCC, FACB, Beckman Coulter,Inc.Allan S. Jaffe, MD, Mayo Clinic

DENKA SEIKEN CO., LTD.Fairmont Hotel, State RoomSmall Dense LDL: Method Validation and Relationship with Severity in StenosisSpeakers: Elizabeth Teng Leary, PhD, Pacific Biometrics, Inc.Shinji Koba, MD, Showa University School of Medicine, Japan

DIAGNOSTIC PRODUCTS CORPORATIONHyatt Regency Chicago, Regency Ballroom BAn Overview of Food Allergies and Co-morbid Conditions: Atopic Dermati-tus (AD) to Eosinophilic Gastrointestinal Disorders (EGID) & MoreSpeaker: Miles Mirhosseini, MD, Diagnostic Products Corporation

FOCUS DIAGNOSTICSFairmont Hotel, Moulin RougeInterpretation of Genetic Tests Using Cystic Fibrosis (CF) as a ParadigmSpeaker: Jean Amos Wilson, PhD, Focus Diag.

ORTHO-CLINICAL DIAGNOSTICSHyatt Regency Chicago, Regency Ballroom CContemporary Issues for the Clinical Laboratory in the Diagnosis and Management of Diabetes MellitisSpeaker: William Roberts, MD, PhD, ARUP, University of Utah Medical Center

ORTHO-CLINICAL DIAGNOSTICSFairmont Hotel, Crystal RoomHepatitus B Virus: Everything I Did Not Learn in SchoolSpeakers: Robert Dufour, MD, George Washington UniversityJ. Schappert, MD, Beth Israel Medical Ctr., N.Y.E. EchevarriaPhD, National Center of Microbiology, SpainP. Kilmartin, PhD, Ortho-Clinical Diagnostics

ROCHE DIAGNOSTICS CORP.Fairmont Hotel, Gold RoomFDA Guidelines for Validation of Rules and a Rules-Sharing WorkshopSpeakers: James Callahan, FDAJon Wearly, FDABill Coughlin, Data Innovation

SEBIA ELECTROPHORESISFairmont Hotel, Regent RoomCapillary Electrophoresis Technology: Recent Menu Expansions Allowing Completely Automated Immunofixation and Hematology Variant TestingSpeaker: Genevieve Hennache, PhD, Parc Technologique Leonard de Vinci, France

WATERS CORPORATIONFairmont Hotel, Imperial BallroomSolving Problems in the Laboratory Using Liquid Chromatography— Tandem Mass Spectrometry (LC/MS/MS)Speakers: David s. Milligan, PhD, Duke University Medical CenterOther speakers TBD

WEDNESDAY, JULY 26

6:00pm–7:30pm

ABBOTT LABORATORIESFairmont Hotel, International BallroomCurrent Trends in Hepatitis and Retrovirus Diagnostic TestingSpeakers: Dr. Philip Cunningham, NSW State Reference Laboratory for HIV, St. Vincent’s Hospital, Darlinghurst, AustraliaBernard Weber, MD, Laboratories Reunis Junglinster, Luxembourg

ABBOTT LABORATORIESFairmont Hotel, Gold RoomImmunoflowcytometry in Routine Hematology (presented a second time)

APPLIED BIOSYSTEMSHyatt Regency Chicago, Regency Ballroom AResults of Recent Clinical Research— HPLC/Tandem Mass SpectroscopySpeakers: TBD

ORTHO-CLINICAL DIAGNOSTICSFairmont Hotel, Crystal roomLean Driven Laboratory DesignSpeakers: Claudia French, BSMT, MBA, Ortho-Clinical DiagnosticsDee Holm, BSMT, MBA, Sacred Heart Hospital, Wash.

ROCHE DIAGNOSTICS CORP.Fairmont Hotel, Moulin RougeCulture Matters! Why?Speaker: June Smart, PhD, MBA, CLD, CLS, Healthcare Solutions

ROCHE DIAGNOSTICS CORP.Hyatt Regency Chicago, Columbus Hall AB Leveraging Analytics to Support Population Outcome StudiesSpeaker: Jay B. Jones, PhD, DABCC, Geisinger Health System

ROCHE DIAGNOSTICS CORP.Fairmont Hotel, State RoomMolecular Technologies—Bridging the Research & Diagnostic LaboratoriesSpeaker: Lonnie Schoft, Roche Diagnostics

ROCHE DIAGNOSTICS CORP.Fairmont Hotel, Regent RoomReal-Time PCR—Hands-on Introductory WorkshopSpeaker: John Osieck, PhD, Roche Diagnostics

SYSMEX AMERICA, INC.Fairmont Hotel, Imperial BallroomMeeting Clinicians’ Needs in Hematology TestingSpeakers: Thomas kickler, MD, Johns Hopkins Medical CenterAnne Tate, Sysmex America, Inc.

More Great Learning Opportunities

As of May 1, 2006


EDITORIAL STAFF




BUSINESS STAFF



BOARD OF EDITORS







AACC OFFICERS






ADVERTISING SALES






SUBSCRIPTIONS








Harvey V. Fineberg, MD, PhDCrossing the Quality Chasm: The Role of Laboratory MedicineSunday, July 23, 5:00–6:30 p.m.

Current Position: President, Institute of Medicine.

Education: Harvard University—MD, 1972; PhD, 1980; BS, 1967.

Previous Positions: Provost, Harvard University; Dean, Harvard School of Public Health.

Dedicated to Public Health

Harvey Fineberg has devoted most of his career to the improvement of public health policy and medical decision making. “To meet the public’s health needs and to fulfill the promise of science for health have never been more compelling social goals,” Fine-berg said when accepting his appointment to become the seventh president of the In-stitute of Medicine (IOM), the position he now holds. Chartered in 1970 by the Na-tional Academy of Sciences (NAS), the IOM enlists distinguished members of the health professions to advise the government on is-sues such as vaccine safety, health care deliv-ery and quality, nutrition standards, cancer prevention and management, and military and veterans’ health.

A member of IOM since 1982, Fineberg chaired the NAS committee that wrote Un-derstanding Risk: Informing Decisions in a Democratic Society and served as either chair or co-chair of the committees that au-thored the reports No Time to Lose: Getting

More from HIV Prevention, America’s Vital Interest in Global Health, Adverse Effects of Pertussis and Rubella Vaccines, and Society’s Choices: Social and Ethical Decision-Making in Biomedicine. His broad research interests encompass AIDS and other infectious dis-eases, the evaluation of diagnostic tests and vaccines, the fields of risk assessment and decision making, the ethical and social im-plications of new medical technologies, and medical education.

Prior to assuming his current role as IOM President, Fineberg served as Provost of Harvard University from 1997–2001, fol-lowing thirteen years as Dean of the Harvard School of Public Health. He was a member of the School’s faculty for eleven years be-fore becoming Dean, during which time he also worked as a practicing physician at two Boston-area health centers. Fineberg helped found and served as president of the Society for Medical Decision Making and has also served as a consultant to the World Health Organization.

Fineberg co-authored The Epidemic that Never Was, an analysis of the controver-sial federal immunization program against swine flu in 1976, and has co-authored and edited several other books on subjects such as HIV prevention and understanding risk. In 1998, he received the Joseph W. Mountain Prize from the Centers for Disease Control and Prevention and the Wade Hampton Frost Prize from the Epidemiology Section of the American Public Health Association.

In his plenary lecture, Fineberg dis-cussed initiatives and activities in the U.S. health care system that emphasize the role of laboratory medicine in bridging the gap that exists between the desired and actual levels of quality in U.S. health care, particu-larly regarding patient safety and medical errors. He identified certain key obstacles that must be overcome to improve the qual-ity of health care delivery, and described the opportunities available for those in labora-tory medicine to contribute to further nar-rowing the “quality chasm.” CLN

Caroline Kovac, PhDComputing in the Age of the GenomeMonday, July 24, 8:45–10:15 a.m. Current Position: General Manager, IBM Pharmaceutical and Life Sciences, Somers, N.Y.

Education: University of Southern California, PhD, Chemistry; Oberlin College, BA

Previous Positions: Vice President, Technical Strategy and Division Operations; Vice President, Services and Solutions, IBM

Professional Activities: Board of Directors, Africa Harvest Biotech Foundation International; Board of Directors, Research!America

Pioneering Life Sciences

Since 2004, Caroline Kovac, PhD has been General Manager and responsible for the strategic direction of IBM’s global phar-maceutical and life sciences business. She and her team develop the latest information technology solutions and services, which includes establishing partnerships and over-seeing IBM investment within the health care, pharmaceutical, and life sciences mar-kets. In this role, Kovac works closely with a wide variety of leaders in health care and life sciences, including medical centers and aca-demic institutions, as well as leading biotech and pharmaceutical companies, to pioneer information-based medicine.

Prior to assuming her present position, Kovac was General Manager of IBM Life Sciences. After its launch as an emerging

business unit with only two employees in 2000, Kovac grew the life sciences business unit into a multi-billion dollar business. The Life Sciences venture is one of IBM’s most successful ventures to date with more than 1,500 employees worldwide. In addition to this position, Kovac has held a number of executive management positions over her more than 20 years at IBM, including vice president of Technical Strategy and Division Operations, and vice president of Services and Solutions. In the latter role, she was in-strumental in launching the Computational Biology Center at IBM Research.

Kovac holds a PhD in Chemistry from the University of Southern California in Los An-geles and a BA from Oberlin College in Ohio. Her professional activities include sitting on the Board of Directors of Africa Harvest Biotech

Foundation International, an organization focused on using technology as a tool to fight hunger, malnutrition and poverty in Africa, and Research!America, an alliance of health care professionals working to increase the re-search investment budgets of federal health care agencies. She is a frequent speaker and panelist at numerous life sciences and health care forums worldwide, and served as an ex-pert panelist for the 2004 World Economic Forum and the 2003 Time Magazine Future of Life Summit. In 2002, Kovac was inducted into the Women in Technology International Hall of Fame, and she is a member-emeritus of the IBM Academy of Technology. In 2004, Kovac was named one of the 50 most power-ful women in business by Fortune magazine and in 2005 won the Scrip Pharmaceutical Executive of the Year Award. CLN

Monday’s Plenary Speaker,Caroline Kovac, PhD


Sunday’s Plenary Speaker,Harvey V. Fineberg, MD, PhD

AACC Members to Elect New Leaders by Electronic Ballot in August

AACC Presidents Take the StageFront row, left to right: Mitchell G. Scott, PhD; Gerald Cooper, MD; Mary Burritt, PhD; Helen Free, DSc; Mary Lou Gantzer, PhD; Larry J. Kricka, PhD, DPhil; John Sherwin, PhD.

Second row, left to right: Donald Young, PhD; Jocelyn Hicks, PhD; Susan Evans, PhD; Peter Wilding, PhD; Laurence Demers, PhD.

Third row, left to right: Thomas Moyer, PhD; Stephen Kahn, PhD; Nathan Gochman, PhD; Frank Sedor, PhD; Jack Ladenson, PhD; Robert Habig, PhD; Carl Burtis, PhD.

Phot

o by C

hrist

ie’s P

hoto

grap

hy, ta

ken

at th

e 200

5 Ann

ual M

eetin

g.

Don’t miss the opportunity to elect the future leaders of AACC. The voting period begins August 1 and ends August 30, and members will receive voting instructions in late July . Further details of the electronic voting process will

be provided in AACC eNews. This election will determine the president-elect for 2007, who will

become the AACC president in 2008. In addition, a treasurer, two members of the board of directors, and four members of the nomi-nating committee will be elected.

P R E S I D E N T -E L E C T

B OA R D O F D I R E C TO R S N O M I N AT I N G C O M M I T T E E

LARRY A. BROUSSARD, PHD, DABCC, FACB

AACC Member: 30 Years

Position: Professor, LSU Health Sciences Center in New Orleans, La. and Di-rector of the Toxicology Laboratory of the Orleans Parish Coroner’s Office.

Excerpt from Broussard’s Platform Statement:My platform statement for the position of Treasurer in 2003 stated that two of the big-gest problems we face as an organization and as individuals are: (1) recognition of the value of clinical diagnostics and the labora-tory in health care and (2) recruitment of young scientists into our profession. In the past 2–3 years the Presidents of AACC have initiated what I’ll call R & R (recognition and recruitment) programs to address these needs and these efforts must be continued.

Recognition of what we do and the value of the services we provide are keys to our survival as a profession. We must continue multiple interactions with clinician organi-zations to demonstrate our abilities to those ordering laboratory tests and receiving the information that we provide. Through ef-forts such as development of practice guide-lines and organization of meetings involving clinician-laboratorian interaction, the Acad-emy of AACC, NACB, is a valuable asset and the continued movement of increased cooperation between AACC and NACB will provide opportunities for the establishment of stronger relationships with clinician or-ganizations. I will work to strengthen such current programs but also to investigate new approaches to our old problems.

In addition to recognition of the value of diagnostic laboratory testing, the recruit-ment of young scientists into our profes-sion is being addressed by AACC, primar-ily through the formation of the Society for Young Clinical Laboratorians. The next step in the process is to ensure that there will be opportunities for training the next genera-tion of laboratorians and I will work to con-tinue and enlarge the AACC programs that have been instituted.

STEVEN H. WONG, PHD

AACC Member: 26 Years

Position: Professor of Pathology, Co-Director, Clinical Chemistry/Toxi-cology, Therapeutic Drug Monitoring (TDM), Phar-macogenomics and Pro-

teomics, Department of Pathology, and Pro-fessor of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, Milwaukee, Wis.; Co-Director, Clinical Chemistry/Toxi-cology, Dynacare Laboratory, Froedtert Lu-theran Memorial Hospital (MCW Teaching Hospital), and LabCorp, Milwaukee, Wis.; and Toxicology Scientific Director, Milwau-kee County Medical Examiner’s Office.

Excerpt from Wong’s Platform Statement:As an association with diverse membership, AACC offers education, networking, and professional development opportunities. I believe that AACC should map out further approaches to train current members, to re-cruit new members, and to encourage young members to be active in the Society of Young Clinical Laboratorians.

With the completion of the human ge-nome project and the emergence of the human proteome, AACC is in a key posi-tion of enhancing the translational research and clinical findings for developing new diagnostics. If elected, I will ensure that functional tests, genomics, proteomics and other “omics” biomarkers are included in the scientific, technological, and regulatory planning processes. If elected, I would sup-port the establishment of a molecular pa-thology review course, a focused effort in membership recruitment, and workshops for mentoring and grants proposals. AACC should extend its outreach to pharmaceuti-cal organizations and the Human Genome Organization.

In summary, I would work to enable the “mutation” of the scientific knowledge base and technological expertise of our well- established discipline to further embrace the opportunities offered by findings of out-come studies in clinical translational medi-cine for patient care.

ANTHONY W. BUTCH, PHD, DABCC, FACB, MT (ASCP)

Professor of Pathology & Labo-ratory Medicine, and Director, Immunology Research Laboratory, Geffen School of Medicine, Univer-

sity of California, Los Angeles, Calif.; Medical Director of Clinical Chemistry, Toxicology, Endocrinology, and Support Services, University Hospital, Los Angeles, Calif.

CATHERINE HAMMETT-STABLER, PHD, DABCC, FACB

Associate Professor, Department of Pathology and Laboratory Medi-cine, University of North Carolina, Chapel Hill, N.C.;

Director, Clinical Toxicology, Clinical Pharmacology, and Pediatric Metabolism Laboratories, and Associate Director, Core Laboratory, McLendon Laboratories, University of North Carolina, N.C.

EMILY S. WINN-DEEN, PHDVice President, Strategic Plan-ning and Business Development, Cepheid, Sunnyvale, Calif.

DANIEL H. FARKAS, PHD, HCLD (ABB), CC, CLSP(MBP), FACBVice-President for Clinical Diagnostics, ChondroGene, Ltd., Toronto, Canada

KEVIN T. CAVANAGH, PHD, FACBDivision Director, Chemistry & Tox-icology, Bureau of Labs, Michigan Department of Community Health, Lansing, Mich.; Laboratory Director,

Saginaw County Department of Public Health, Saginaw, Mich.; Associate Adjunct Professor, Department of Medical Technology, Michigan State University.

DAVID GRENACHE, PHD, MT(ASCP) Assistant Professor of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, N.C.; Associate Direc-

tor, Core Laboratory, and Director, Special Chemistry and Blood Gas Laboratories, UNC Hospitals, Chapel Hill, N.C.

PATRICIA M. JONES, PHD, DABCC, FACB Associate Professor, Pathology and Medical Laboratory Science, UT Southwestern Medical Center; Clinical Director, Chemistry and

Client Services, Children’s Medical Center, Dallas, Texas.

INGO S. KAMPA, PHD Manager, Special Procedures Labo-ratory, Valley Hospital, Ridgewood, N.J.; Consultant, K&K Associates, Inc.

LARRY J. KRICKA, DPHIL

Professor of Pathology and Labo-ratory Medicine, University of Pennsylvania, and Director, General Chemistry Laboratory, Hospital of

the University of Pennsylvania, Philadelphia, Pa.

JOSEPH P. MCCONNELL, PHD, DABCCLaboratory Director, Department of Laboratory Medicine (DLMP), and Co-Director, Immunochemical Core Laboratory, Department of Research,

Mayo Clinic, Rochester, Minn.; Assistant Pro-fessor, Laboratory Medicine, Mayo Graduate School of Medicine, Rochester, Minn.

A A C CNATIONAL ELECTIONS

SLATE OF CANDIDATES


T R E A S U R E R

ANN GRONOWSKI, PHD, DABCC, FACBAssociate Professor, Washington University School of Medicine, De-partments of Pathology & Immu-nology and Obstetrics & Gynecol-

ogy, St. Louis, Mo.; Associate Medical Director, Clinical Chemistry, Serology and Immunol-ogy, Barnes-Jewish Hospital, St. Louis, Mo.

JAMES H. NICHOLS, PHD, DABCC, FACBAssociate Professor, Pathology, Tufts University School of Medicine, Boston, Mass.; Medical Director, Clinical Chemistry, Baystate Health,

Springfield, Mass.

Documents

Announcements 06